Patents by Inventor Anna Skottner

Anna Skottner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel melanocortin receptor agonists and antagonists
    Publication number: 20030195212
    Abstract: The present invention relates to novel aromatic amines of general formula (I) and to the use of these amines for the treatment of obesity, anorexia, inflammation, mental disorders an other diseases associated with the melanocortin receptors or related systems, e.g. the melanocyte stimulating hormones.
    Type: Application
    Filed: November 20, 2002
    Publication date: October 16, 2003
    Inventors: Torbjorn Lundstedt, Anna Skottner, Elisabeth Seifert, Igor Starchenkov, Peteris Trapencieris, Valerjans Kauss, Ivars Kalvins, Arne Boman
  • Treatment of catabolic states using authentic IGF-1 and hypocaloric amount of nutrients
    Patent number: 6034059
    Abstract: IGF-1 and a hypocaloric amount of nutrient are used to treat a catabolic state in a patient. The IGF-1 and nutrient can be administered simultaneously, separately or sequentially. The amounts of IGF-1 and hypocaloric amount of nutrient are effective for the treatment of the catabolic state.
    Type: Grant
    Filed: March 17, 1993
    Date of Patent: March 7, 2000
    Assignee: Chiron Corporation
    Inventors: Linda Fryklund, Peter Gluckman, Anna Skottner
  • Use of insulin and IGF-I
    Patent number: 5994303
    Abstract: A combination of insulin and an insulin-like growth factor I (IGF-I) as used in the manufacture of a medicament for counteracting a decrease in nitrogen balance and for counteracting a decrease in protein synthesis. The medicament can be used for the treatment of catabolism which is a protein catabolism due to glucocorticoid excess.
    Type: Grant
    Filed: January 5, 1998
    Date of Patent: November 30, 1999
    Assignee: Chiron Corporation
    Inventors: Vibeke Arrhenius-Nyberg, Kjell Malmlof, Anna Skottner
  • Insulin-like growth factor II as antitumour agent
    Patent number: 5902788
    Abstract: The invention relates to the use of IGF-II for the manufacture of a medicament for the treatment of tumours, and especially for the manufacture of a medicament for growth inhibition of melanoma cells and for the treatment of cutaneous melanomas. The medicament can be systemically or locally administered.
    Type: Grant
    Filed: May 15, 1996
    Date of Patent: May 11, 1999
    Assignee: Pharmacia & Upjohn Aktiebolag
    Inventors: Paul Schofield, Robert Charles Rees, Amardip Singh Bhuller, Anna Skottner-Lundin
  • Use of insulin and IGF-1
    Patent number: 5756463
    Abstract: A method is disclosed for counteracting a decrease in nitrogen balance and counteracting a decrease in protein synthesis in an individual, comprising administering to the individual a combination of insulin and IGF-I.
    Type: Grant
    Filed: December 18, 1996
    Date of Patent: May 26, 1998
    Assignee: Pharmacia & Upjohn AB
    Inventors: Vibeke Arrhenius-Nyberg, Kjell Malmlof, Anna Skottner
  • Use of human IGF-1 to treat cardiac disorders
    Patent number: 5434134
    Abstract: Human IGF-I or effective analogues thereof are used for preventing or treating cardiac disorders. Compositions are also provided that comprise human IGF-I or effective analogues thereof together with additional proteins or peptides such as other growth factors, hormones, binding proteins or receptors for enhancing or improving the desired effects of IGF-I or its effective analogues and possibly pharmaceutically acceptable carrier or diluent for the prevention or treatment of cardiac disorders.
    Type: Grant
    Filed: October 7, 1993
    Date of Patent: July 18, 1995
    Assignee: Pharmac IA AB
    Inventors: Peter Gluckman, Anna Skottner
  • Method of improving regeneration of transfected peripheral nerves using IGF-1
    Patent number: 5068224
    Abstract: A method for improving the regeneration of transected peripheral nerves in mammals and man, by administering a sufficient amount of insulin-like growth factor 1 (IGF-1) to a mammalian host in need of such treatment. If desired, administration of the medicament containing insulin like growth factor can be carried out locally by infusion.
    Type: Grant
    Filed: September 16, 1988
    Date of Patent: November 26, 1991
    Assignee: KabiVitrum AB
    Inventors: Linda Fryklund, Hans A. Hansson, Martin Kanje, Anna Skottner